Please enable Javascript
Daniel A. González-Padilla
Daniel A. González-Padilla, Clínica Universidad de Navarra (Spain)
Articles by Daniel A. González-Padilla
Methodological Concerns in PARP Inhibitor Trials Leave Unanswered Questions for mCRPC
Daniel A. González-Padilla
CRPC
|
October 31, 2023
Dr. González-Padilla shares his thoughts on the methodological concerns of TRITON3 and PROfound for treating mCRPC patients.
View More